Epigenetic therapies have shown promise both as monotherapy and in combination strategies and specifically histone lysine demethylase, KDM4A (Lysine demethylase 4), plays a role in the maintenance of AML, with its short hairpin (shRNA) knockdown sufficient to target leukaemia cells while sparing normal haemopoietic cells. This evidence concerns the gene KDM4A and leukemia.